Industry
Biotechnology
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Loading...
Open
1.47
Mkt cap
104M
Volume
239K
High
1.47
P/E Ratio
-1.58
52-wk high
2.75
Low
1.37
Div yield
N/A
52-wk low
0.85
Portfolio Pulse from
November 06, 2024 | 9:30 pm
Portfolio Pulse from Benzinga Insights
October 22, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 5:21 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 11:37 am
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 9:26 pm
Portfolio Pulse from Benzinga Newsdesk
June 05, 2024 | 2:48 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 9:40 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 2:43 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 8:24 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.